The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine - Müller, N; Schwarz, M J; Dehning, S; Douhe, A; Cerovecki, A; Goldstein-Müller, B; Spellmann, I; Hetzel, G; Maino, K; Kleindienst, N; Möller, H-J; Arolt, V; et al. (Molecular psychiatry, 2006)
Keywords: Adrenergic Uptake Inhibitors; Adult; Adult and adolescent clinical studies; Anti-Anxiety Agents - administration & dosage; Anti-Anxiety Agents - therapeutic use; Anti-inflammatory agents; Antidepressive Agents - administration & dosage; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Celecoxib; Cyclooxygenase 2 Inhibitors - administration & dosage; Cyclooxygenase 2 Inhibitors - pharmacology; Cyclooxygenase 2 Inhibitors - therapeutic use; Cyclooxygenase-2; Cytokines; Depression; Depressive Disorder - drug therapy; Depressive Disorder - physiopathology; Dinoprostone - analysis; Dinoprostone - biosynthesis; Double-Blind Method; Double-blind studies; Drug Therapy, Combination; Female; Humans; Inflammation; Inflammation - drug therapy; Inflammation - physiopathology; Interleukin-6 - biosynthesis; Lorazepam - administration & dosage; Lorazepam - therapeutic use; Male; Medical sciences; Medicine; Medicine & Public Health; Mental depression; Middle Aged; Mood disorders; Morpholines - administration & dosage; Morpholines - therapeutic use; Neuropharmacology; Neurosciences; original-article; Patient Dropouts; Patients; Pharmacology. Drug treatments; Pharmacotherapy; Pilot Projects; Placebos; Plasma levels; Prostaglandin E2; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychological Tests; Psychology. Psychoanalysis. Psychiatry; Psychopathology; Psychopathology. Psychiatry; Psychopharmacology; Pyrazoles - administration & dosage; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; Reboxetine; Serotonin - metabolism; Severity of Illness Index; Sulfonamides - administration & dosage; Sulfonamides - pharmacology; Sulfonamides - therapeutic use; psychoneuroimmunology; COX-2 inhibition; immunity; inflammation; major depression; Prostaglandin-endoperoxide synthase; Psychotropic; Cyclooxygenase 2 inhibitor; Reuptake inhibitor; Antidepressant agent; Inhibition; Mood disorder; Human; Reboxetine; Enzyme; Enzyme inhibitor; Depression; Inflammation; Celecoxib; Catecholamine; Chemotherapy; Treatment; Placebo; Neurotransmitter; Double blind study; Norepinephrine; Oxidoreductases